- Company
- Rise of new drugs... subject of NA and public petitions
- by Eo, Yun-Ho Apr 7, 2023 05:54am
- Specific product names of new drugs are being mentioned at the National Assembly audit and public petitions calling for the application of reimbursement for specific drugs have gathered 50,000 consents. Such activities, which would not have happened 5 years ago, are actually arising in Korea. The emergence of government affairs (GA) and p
- Company
- LG Chem releases DPP-4+SGLT-2 combo Zemidapa Tab
- by Kim, Jin-Gu Apr 6, 2023 05:53am
- On the 4th, LG Chem announced it will be releasing its new antidiabetic combination drug ‘Zemidapa Tab’ on the 8th. Zemidapa is a fixed-dose combination of the DPP-4 inhibitor class market leader Zemiglo (gemigliptin) and SGLT-2 inhibitor class market leader dapagliflozin (Product name: Forxiga). Zemidapa is the only option that offers
- Company
- NeuroBo, a subsidiary of Dong-A ST, applies for NASH candida
- by Apr 6, 2023 05:53am
- Dong-A ST announced on the 4th that its US subsidiary NeuroBo Pharmaceuticals has applied to the US Food and Drug Administration (FDA) for a phase 2 clinical trial plan for NASH treatment candidate DA-1241. This clinical trial will be conducted for 16 weeks on 87 patients with NASH. It is a multicenter, randomized, double-blind, placebo-contr
- Company
- Zuellig Pharma Korea turns profitable in 6 years
- by Apr 6, 2023 05:53am
- Zuellig Pharma Korea, a global drug distribution company, escaped from complete capital impairment last year (total capital was negative). Operating profit also turned to black for the first time in six years. We are concentrating our efforts on improving performance by significantly reducing SG&A. According to the Financial Supervisory Servi
- Company
- Onureg, PO acute leukemia drug, is scheduled to be proposed
- by Eo, Yun-Ho Apr 6, 2023 05:53am
- Onureg, a maintenance therapy for acute myeloid leukemia, is on its way to entering insurance coverage. As a result of the coverage, Onureg is scheduled to be presented to the Pharmaceutical Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service on the 6th. It has been about four months since the passage of t
- Company
- Patients and policy are trending in the pharma industry
- by Eo, Yun-Ho Apr 6, 2023 05:53am
- The opening of new positions that didn’t exist before indicates the considerable need for the positions. Recently, Korean subsidiaries of multinational pharmaceutical companies that mainly supply new drugs have opened up two new positions - GA (Government Affairs) and PA (Patient Advocacy). The changes seem to be in line with the trend
- Company
- Active M&A for global cell and gene therapy
- by Hwang, Jin-joon Apr 5, 2023 05:47am
- In the field of cell and gene therapy, which is considered a next-generation drug, an M&A worth 3.4 trillion won was completed. Domestic biopharmaceutical companies are conducting R&D in the field of cell and gene therapy as a future food source. CDMO companies are entering the CDMO business for cell and gene therapy through M&A and factory e
- Company
- Celltrion discloses interim results of global phase 3 Eylea
- by Hwang, Jin-joon Apr 5, 2023 05:45am
- On the 3rd, Celltrion disclosed the interim results based on the 24th week of the global phase 3 clinical trial of CT-P42, an eye disease treatment Eylea biosimilar. Celltrion is conducting clinical trials for 52 weeks on 348 DME patients in 13 countries, including Germany and Spain. The interim results released this time are the results of c
- Company
- CHMP gave a positive opinion on the approval of Soliris
- by Jung, Sae-Im Apr 5, 2023 05:44am
- On the 31st of last month, Samsung Bioepis announced that it had obtained a positive opinion for the item approval of 'EPYSQLITM (Eculizumab)', a treatment for rare diseases, from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA). EPYSQLITM is a biosimilar of Alexion's paroxysmal nocturnal hem
- Company
- Hanmi internationally introduces 7 new drug candidates
- by Hwang, Jin-joon Apr 4, 2023 05:53am
- Hanmi Pharmaceutical is revealing its messenger ribonucleic acid (mRNA) cancer vaccine and new targeted anticancer lead compounds. The company reinforced its anticancer pipeline by adding next-generation anticancer drug technologies and targets to its existing major anticancer drug pipeline that has been making smooth progress in preclinical
